Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCN 2021 | Analysis of neurotransmitter metabolites in CSF in Parkinson’s Disease

Brit Mollenhauer, MD, University Medical Center Göttingen, Göttingen, Germany, discusses a longitudinal analysis of multiple neurotransmitter metabolites in cerebrospinal fluid (CSF) in early Parkinson’s disease (PD). Results showed that baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with healthy controls. However, Dr Mollenhauer explains that initially, they expected a more marked decrease in the PD subjects. Although the method used in the study needs to be validated in a larger cohort, it could be an interesting addition to other biomarkers. This interview took place during the XXV World Congress of Neurology.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.